Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Risedronate 75mg 2 Consecutive Days Monthly vs 5mg Daily in Postmenopausal Osteoporosis
NCT00358176Phase 3Completed
- Sponsor
- Sanofi
- Start
- Jul 2004
- Primary completion
- Mar 2007
- Modality
- Small Molecules
- Countries
- 11
01
Overview
Phase 3, randomised, double-blind trial of risedronate in postmenopausal osteoporosis (2 arms), sponsored by Sanofi. Primary endpoint: Percent change from baseline in lumbar spine bone mineral density (BMD) at 12 months. Started Jul 2004; status: completed.
02
Drugs
risedronate
03
Conditions
postmenopausal osteoporosis
Beyond the preview
Go deeper on NCT00358176.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00358176.